Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2025 update
• Spotlight

About Prescrire

• Editorial policies
• How we work
• AMP: non-profit
• Financing
• No conflicts of interest
• Where to find us
• About Prescrire International
• Citations in other journals
• A global network

Offers

• Subscribe or renew my subscription
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

english.prescrire.org

Prescrire's other websites

Prescrire.org Formations Prescrire Prescrire Campus Éviter l'Évitable

In Prescrire's Spotlight

Take action  Editorial  Many drugs that have been marketed for decades have become such a part of routine practice that they are taken for granted. Some are useful, with demonstrated efficacy and an acceptable adverse effect profile. Some others have no demonstrated clinical value beyond that of a placebo, and it is debatable whether they should remain on the market. Full article available for download (FREE) 1 February 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid in the name of better patient care: 2025 update  DRUGS TO AVOID - 2025 UPDATE  To make it easier to choose high-quality care, and to prevent disproportionate harm to patients, Prescrire has published its annual update of drugs to avoid on the basis that they are more dangerous than beneficial. Full article (11 pages) available for download (FREE) 1 February 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Dostarlimab (Jemperli°) in advanced or recurrent endometrial cancer with DNA repair defects  Marketing Authorisations  Dostarlimab is an immunostimulatory anti-PD-1 antibody that has been authorised in the European Union for use in patients with advanced or recurrent mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) endometrial cancer, either in first-line treatment in combination with carboplatin and paclitaxel, or in second-line treatment as monotherapy. Full article available for download by subscribers 1 February 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Mavacamten (Camzyos°) in hypertrophic cardiomyopathy?  Marketing Authorisations  Mavacamten, described as a selective and reversible inhibitor of cardiac myosin, has been authorised in the European Union in the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Does it extend survival in this situation, alleviate the symptoms of the disease (especially compared with a beta blocker or a calcium-channel blocker), reduce the incidence of serious complications, and avert the need for heart surgery? And what are its adverse effects? Full article (3 pages) available for download by subscribers 1 February 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Intravitreal VEGF inhibitors: systemic adverse effects  Adverse Effects  A pharmacovigilance survey carried out by the French Health Products Agency (ANSM) identified 130 reports of cardiovascular adverse effects, mainly stroke, in patients treated with an intravitreal VEGF inhibitor. Two epidemiological studies, one conducted in the US and the other in Taiwan, quantified the risk of cardiovascular or kidney disease associated with intravitreal exposure to VEGF inhibitors. Full article available for download by subscribers 1 February 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON•  Exagamglogene autotemcel in beta-thalassaemia and sickle-cell disease • Anticoagulants and heavy menstrual bleeding • Children exposed to progestogens in utero • Prevention of errors related to authorised brand names  > Subscribe now 1 February 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19: Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of articles featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help health professionals gain a clear and balanced view. 1 November 2023

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ New! "2025 Free Special Edition", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this selection of articles to introduce you to Prescrire International, a wholly independent monthly drug bulletin, written by and for healthcare professionals. Includes an array of articles from the past year on drugs and health policy in Europe. > Click here for your free copy 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International  SUBSCRIBE NOW!  Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 165 euros (less for students and residents of lower-income countries). 1 January 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on LinkedIn, Facebook and X Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on LinkedIn, > Follow us on Facebook or > Follow us on X 1 January 2025

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 July 2022

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2025 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page

---